文献速递免疫规划传染病防控与疫情报告职业卫生

第二剂新冠疫苗加强针对医护人员实验室确诊SARS-CoV-2感染的相对疫苗有效性:VEBIS HCW VE队列研究(2022年10月1日至2023年5月2日)

Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023).
PubMed 文献 · Vaccine · 2024-12-25

该前瞻性队列研究纳入12家欧洲医院的979名医护人员,评估第二剂相比第一剂新冠疫苗加强针对实验室确诊SARS-CoV-2感染的相对疫苗有效性(rVE)。第二剂加强针总体rVE为-5%(95%CI:-46;25),接种后7-89天为3%(95%CI:-46;36),仅使用二价疫苗时为11%(95%CI:-43;45)。作者指出因部分使用单价疫苗、样本量小及XBB.1.5流行,rVE估计不精确。

要点

  • 979名医护人员中392人(40%)接种第二剂加强针,192人(20%)研究期间感染。
  • 第二剂相比第一剂加强针总体rVE为-5%(95%CI:-46;25),7-89天为3%(95%CI:-46;36)。
  • 仅使用二价疫苗时rVE为11%(95%CI:-43;45),但估计不精确。

核心结论

  • 二价新冠疫苗可能使医护人员SARS-CoV-2感染风险降低11%,但rVE估计不精确。

研究设计与样本

  • 前瞻性队列研究,纳入12家欧洲医院的979名符合第二剂加强针接种条件的医护人员,2022年10月至2023年5月每周或每两周随访采集鼻咽或唾液样本。

主要发现

  • 979名医护人员中392人(40%)接种第二剂加强针,192人(20%)研究期间感染。
  • 第二剂相比第一剂加强针总体rVE为-5%(95%CI:-46;25),接种后7-89天为3%(95%CI:-46;36)。
  • 仅使用二价疫苗时rVE为11%(95%CI:-43;45)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • rVE估计不精确,因研究中部分使用单价疫苗、样本量小及研究期间XBB.1.5亚系流行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Repeated COVID-19 booster vaccination was recommended in healthcare workers (HCWs) to maintain protection. We measured the relative vaccine effectiveness (rVE) of the second booster dose of COVID-19 vaccine compared to the first booster, against laboratory-confirmed SARS-CoV-2 infection in HCWs. METHODS: In a prospective cohort study among HCWs from 12 European hospitals, we collected nasopharyngeal or saliva samples at enrolment and during weekly/fortnightly follow-up between October 2022 and May 2023. We estimated rVE of the second versus first COVID-19 vaccine booster dose against SARS-CoV-2 infection, overall, by time since second booster and restricted to the bivalent vaccines only. Using Cox regression, we calculated the rVE as (1-hazard ratio)*100, adjusting for hospital, age, sex, prior SARS-CoV-2 infection and at least one underlying condition. RESULTS: Among the 979 included HCWs eligible for a second booster vaccination, 392 (40 %) received it and 192 (20 %) presented an infection during the study period. The rVE of the second versus first booster dose was -5 % (95 %CI: -46; 25) overall, 3 % (-46; 36) in the 7-89 days after receiving the second booster dose. The rVE was 11 % (-43; 45) when restricted to the use of bivalent vaccines only. CONCLUSION: The bivalent COVID-19 could have reduced the risk of SARS-CoV-2 infection among HCWs by 11 %. However, we note the limitation of imprecise rVE estimates due to the proportion of monovalent vaccine used in the study, the small sample size and the study being conducted during the predominant circulation of XBB.1.5 sub-lineage. COVID-19 vaccine effectiveness studies in HCWs can provide important evidence to inform the optimal timing and the use of updated COVID-19 vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Savulescu C, Prats-Uribe A, Brolin K, et al. Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023). Vaccine. 2024. PMID: 39724693. doi:10.1016/j.vaccine.2024.126615

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。